Edap Tms SA

Edap Tms SA(FOCL)股票分析

$4.340

+0.243 (+5.60%)收盤時

Loading chart…
最高
4.400
開盤
4.240
成交量加權均價
4.33
成交量
7.93K
市值
—
最低
4.240
成交金額
34.31K
企業價值/稅息折舊攤銷前利潤(TTM)
-5.24

Edap Tms SA is a France-based company that develops, manufactures, promotes and distributes minimally invasive medical devices for urology based upon ultrasound technology. The Company's activity is organized in two divisions: HIFU (High Intensity Focused Ultrasound) and ESWL (Extracorporeal ShockWave Lithotripsy) that invests in research and development, partnering with INSERM French public laboratory and international medical research institutions. It specialises in HIFU technology, a non-invasive treatment of prostate conditions with a range of Robotic HIFU devices, Ablatherm Fusion and Focal One, ESWL and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications. It also operates worldwide via a network of corporate offices, subsidiaries and distribution partners

AI 分析 of Edap Tms SA (FOCL)

買進

Edap Tms SA (FOCL) appears to be a good buy right now, trading at $4.34 with a strong RSI of 62.29 indicating bullish momentum. The company's gross margin has improved significantly to 55.58%, up from 42.52% in the previous year, showcasing operational efficiency. Additionally, analysts have set a price target of $15 from Mizuho, suggesting a potential upside of over 245% from the current price. However, the main risk is the negative earnings per share forecast of -0.18 for the next earnings report, which could impact investor sentiment.

估值指標

Edap Tms SA(FOCL)目前預期本益比為 38.91,5 年平均預期本益比為 38.91。

預期本益比

合理
5 年均值 P/E
38.91
目前P/E
38.91
高估
38.91
低估
38.91

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-6.00
目前EV/EBITDA
-5.24
高估
-4.78
低估
-7.22

預期股價營收比

合理
5 年均值 P/S
2.79
目前P/S
2.78
高估
3.04
低估
2.54

持有 FOCL 的大戶

S

Soleus Capital Management, L.P.

+ 持有FOCL

-7.34%

3個月報酬率

事件時間軸

2026-08-14 (ET)

12:00:00

Major Averages Broadly Lower Near Noon

2026-08-13 (ET)

16:30:00

FocalTherics Q2 Revenue at $13.2M, Below Expectations

16:30:00

Company Announces ESWL and Distribution Segments as Discontinued Operations

2026-08-11 (ET)

21:30:00

TD Cowen and Mizuho Jointly Manage Offering

17:00:00

Sees Q2 Gross Margin at 54%-56%

資訊

FOCL 常見問題 —— 由 Alphio AI 解答

Edap Tms SA is a France-based company that develops, manufactures, promotes and distributes minimally invasive medical devices for urology based upon ultrasound technology. The Company's activity is organized in two divisions: HIFU (High Intensity Focused Ultrasound) and ESWL (Extracorporeal ShockWave Lithotripsy) that invests in research and development, partnering with INSERM French public laboratory and international medical research institutions. It specialises in HIFU technology, a non-invasive treatment of prostate conditions with a range of Robotic HIFU devices, Ablatherm Fusion and Focal One, ESWL and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications. It also operates worldwide via a network of corporate offices, subsidiaries and distribution partners It operates in the Healthcare sector.

Edap Tms SA (FOCL) appears to be a good buy right now, trading at $4.34 with a strong RSI of 62.29 indicating bullish momentum. The company's gross margin has improved significantly to 55.58%, up from 42.52% in the previous year, showcasing operational efficiency. Additionally, analysts have set a price target of $15 from Mizuho, suggesting a potential upside of over 245% from the current price. However, the main risk is the negative earnings per share forecast of -0.18 for the next earnings report, which could impact investor sentiment.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易